Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New medical application of polyethylene glycol loxenatide or pharmaceutical composition thereof

A polyethylene glycol and composition technology, applied in the field of biomedicine, can solve the problems of research on the treatment effect of type II diabetes patients, and the treatment effect of type II diabetes patients without polyethylene glycol loxenatide, and achieve significant myocardial Protective effect, protection of liver damage, effect of alleviating liver fibrosis

Active Publication Date: 2021-12-31
SHANGHAI HANSOH BIOMEDICAL +2
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, there is no research on the treatment of polyethylene glycol loxenatide for liver disease, and there is no research on the therapeutic effect of type 2 diabetes patients with liver damage or fatty liver, hepatitis, and liver fibrosis. There is also no research on the therapeutic effect of polyethylene glycol loxenatide on type 2 diabetes patients with myocardial damage, so it is urgent to conduct in-depth research on related treatment options to provide more treatment options for clinical patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New medical application of polyethylene glycol loxenatide or pharmaceutical composition thereof
  • New medical application of polyethylene glycol loxenatide or pharmaceutical composition thereof
  • New medical application of polyethylene glycol loxenatide or pharmaceutical composition thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1. PEG-Loxe improves lipid disorders in T2DM mice

[0045] 1.1 Experimental method

[0046] Blood samples were immediately centrifuged (1200 g, 4°C, 15 min) to obtain serum. The levels of TC, TG, HDL-C, LDL-C, HbA1c and insulin in serum were detected by automatic biochemical analyzer (BS-420, Mindray, China).

[0047] The liver tissue was homogenized with 9× (wt / vol) ice-cold phosphate-buffered saline, then centrifuged at 3500 rpm for 15 min, and the supernatant was collected. According to the manufacturer's instructions, ELISA kits were used to detect lipids (TC, TG, HDL-C, LDL-C), AST, ALT), oxidative factors (ROS, MDA, SOD, GSH, CAT) and inflammation in liver tissue. Sex factor (IL-10, TNF-α, IL-6, MCP-1) content.

[0048] 1.2 Experimental results

[0049] Table 1. PEG-Loxe can improve the levels of various biochemical parameters in db / db mice

[0050]

[0051] Note: NC is the normal control group; T2DM is the type 2 diabetes group. Data are expresse...

Embodiment 2

[0054] Example 2. PEG-Loxe improves hepatic steatosis and liver injury in T2DM mice

[0055] 1.1 Experimental method

[0056] Animal liver and pancreas tissues were fixed in 10% formalin solution, dehydrated and embedded in paraffin. Embedded sections (3-5 μm thickness) were stained with hematoxylin and eosin (H&E) for histopathological analysis. Liver sections were stained with Sirius Red and Oil Red O, and all sections were observed and captured at 400× using an Olympus BX51 microscope (Tokyo, Japan).

[0057] 1.2 Experimental results

[0058] H&E staining of liver sections showed that the hepatocytes in the blank group were regular in shape, evenly distributed and tightly arranged; cytoplasmic vacuoles and hepatocyte necrosis appeared in T2DM mice. However, after 4 weeks of treatment with PEG-Loxe, Lira, and Loxe, liver lesions were significantly reduced (attached figure 1 A). In order to evaluate the liver damage in T2DM mice, we measured the levels of ALT and AST in ...

Embodiment 3

[0063] Example 3: PEG-Loxe reduces hepatic oxidative stress and inflammatory response in T2DM mice

[0064] 1.1 Experimental method

[0065] The liver tissue was homogenized with 9× (wt / vol) ice-cold phosphate-buffered saline, then centrifuged at 3500 rpm for 15 min, and the supernatant was collected. According to the manufacturer's instructions, ELISA kits were used to detect lipids (TC, TG, HDL-C, LDL-C), AST, ALT), oxidative factors (ROS, MDA, SOD, GSH, CAT) and inflammation in liver tissue. Sex factor (IL-10, TNF-α, IL-6, MCP-1) content.

[0066] ROS production in the liver was further detected by DHE staining. Briefly, 10 μm thick frozen liver tissues were obtained for sectioning using a cryostat (CM1900, Leica, Germany). Subsequently, the tissue was incubated with 5 mmol / L fluorescently labeled DHE for 30 min at 37°C in a dark environment, DHE was diluted 1:1000, and then treated with 4',6'-diamino-2-phenylindole (DAPI , AS1075, Aspen Biological, Wuhan, China) staini...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological medicines and relates to medical application of polyethylene glycol loxenatide or a pharmaceutical composition thereof. Specifically, the invention provides application of the polyethylene glycol loxenatide or the pharmaceutical composition thereof in preparation of a medicine for treating / preventing liver diseases or a medicine for treating / preventing myocardial injury. The new medical application of the polyethylene glycol loxenatide or the pharmaceutical composition thereof, provided by the invention, has a wide clinical application prospect.

Description

technical field [0001] The invention belongs to the field of biomedicine, and specifically relates to the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) polyethylene glycol loxenatide or its pharmaceutical composition in the preparation of drugs for treating or preventing liver diseases . Background technique [0002] Diabetes is a metabolic disorder caused by a variety of etiologies. According to the statistics of the International Diabetes Federation (IDF), there were more than 371 million diabetic patients worldwide in 2012, and the death toll was as high as 4.8 million. It is estimated that there will be nearly 552 million patients worldwide by 2030. Among them, type II diabetes patients accounted for more than 90%. Long-term chronic hyperglycemia can lead to various complications, including liver, kidney, cardiovascular and retinal damage, etc., which brings a huge economic burden to the world's medical system. Currently, the treatment drugs for type II ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/60A61K38/22A61P1/16A61P3/10A61P9/04
CPCA61K47/60A61K38/22A61P1/16A61P3/10A61P9/04
Inventor 张玉王凯平赵军军史琛张琪琳李玉峰
Owner SHANGHAI HANSOH BIOMEDICAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com